华东医药
(000963)
| 流通市值：510.30亿 | | | 总市值：510.51亿 |
| 流通股本：17.53亿 | | | 总股本：17.54亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 11,183,450,824.27 | 43,612,009,891.02 | 32,664,143,135.68 | 21,674,928,965.21 |
| 营业收入 | 11,183,450,824.27 | 43,612,009,891.02 | 32,664,143,135.68 | 21,674,928,965.21 |
| 二、营业总成本 | 9,992,872,896.34 | 39,388,881,033.06 | 29,289,598,185.1 | 19,418,419,774.58 |
| 营业成本 | 7,387,443,870.04 | 29,499,479,451.02 | 21,715,689,459.85 | 14,327,396,132.9 |
| 税金及附加 | 67,774,008.09 | 246,544,789.96 | 172,981,938.92 | 114,585,169.4 |
| 销售费用 | 1,820,619,488.78 | 6,526,826,370.64 | 4,791,980,345.55 | 3,229,044,236.81 |
| 管理费用 | 371,395,501.48 | 1,344,109,556.03 | 1,090,027,991.29 | 725,296,086.8 |
| 研发费用 | 350,365,327.14 | 1,753,147,744.43 | 1,507,590,822.48 | 999,673,972.93 |
| 财务费用 | -4,725,299.19 | 18,773,120.98 | 11,327,627.01 | 22,424,175.74 |
| 其中:利息费用 | 19,176,576.84 | 94,734,093.6 | 86,551,703.07 | 56,147,464.39 |
| 其中:利息收入 | 20,155,981.89 | 82,517,322.89 | 72,327,993.36 | 45,613,834.96 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -22,310,345.97 | -137,842,753.21 | -119,368,076.22 | -67,265,820.65 |
| 资产处置收益 | 534,949.84 | 2,263,396.06 | 1,817,243.94 | -6,201,002.36 |
| 资产减值损失(新) | - | -87,895,771.71 | - | - |
| 信用减值损失(新) | - | -136,912,856 | -83,959,366.71 | -83,959,366.71 |
| 其他收益 | 31,230,304.02 | 245,152,017.73 | 177,555,419.45 | 144,290,664.93 |
| 四、营业利润 | 1,200,032,835.82 | 4,107,892,890.83 | 3,350,590,171.04 | 2,243,373,665.84 |
| 加:营业外收入 | 1,256,954.75 | 34,205,807.33 | 5,639,215.91 | 4,157,614.19 |
| 减:营业外支出 | 9,095,444.64 | 125,636,387.92 | 93,607,836.34 | 54,367,929.24 |
| 五、利润总额 | 1,192,194,345.93 | 4,016,462,310.24 | 3,262,621,550.61 | 2,193,163,350.79 |
| 减:所得税费用 | 195,032,945.55 | 605,615,537.79 | 520,763,289.42 | 389,834,341.82 |
| 六、净利润 | 997,161,400.38 | 3,410,846,772.45 | 2,741,858,261.19 | 1,803,329,008.97 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 997,161,400.38 | 3,410,846,772.45 | 2,741,858,261.19 | 1,803,329,008.97 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 1,002,189,357.16 | 3,414,335,326.41 | 2,747,916,019.11 | 1,814,826,860.86 |
| 少数股东损益 | -5,027,956.78 | -3,488,553.96 | -6,057,757.92 | -11,497,851.89 |
| 扣除非经常损益后的净利润 | 989,719,668.99 | 3,311,448,470.6 | 2,693,515,147.85 | 1,761,734,255.98 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.57 | 1.95 | 1.57 | 1.03 |
| (二)稀释每股收益 | 0.57 | 1.95 | 1.57 | 1.03 |
| 八、其他综合收益 | -80,607,620.61 | 56,368,891.24 | 83,361,634.41 | 23,756,112.05 |
| 归属于母公司股东的其他综合收益 | -80,607,620.61 | 56,368,891.24 | 83,361,634.41 | 23,756,112.05 |
| 九、综合收益总额 | 916,553,779.77 | 3,467,215,663.69 | 2,825,219,895.6 | 1,827,085,121.02 |
| 归属于母公司股东的综合收益总额 | 921,581,736.55 | 3,470,704,217.65 | 2,831,277,653.52 | 1,838,582,972.91 |
| 归属于少数股东的综合收益总额 | -5,027,956.78 | -3,488,553.96 | -6,057,757.92 | -11,497,851.89 |
| 公告日期 | 2026-04-24 | 2026-04-24 | 2025-10-28 | 2025-08-20 |
| 审计意见(境内) | | 标准无保留意见 | | |